Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study retrospectively analyzed 14 postmenopausal women with frontal fibrosing alopecia, noting that 57% experienced total eyebrow loss, and all received various steroid treatments, highlighting the importance of early diagnosis to potentially delay disease progression.

This study developed a handheld card to simplify the calculation of the SALT score for assessing alopecia areata severity, noting that while it accelerates the process, formal validation against existing methods is still needed.

This study found that the Polish version of the AA-QLI questionnaire is a reliable and internally consistent tool for assessing health-related quality of life in Polish-speaking patients with alopecia areata.

Abatacept may help some people with alopecia areata regrow hair.

This case report describes frontal fibrosing alopecia in a woman with primary biliary cirrhosis and polymyalgia rheumatica, suggesting a possible autoimmune link to this form of hair loss.

This article includes no new results; it discusses ongoing treatment approaches for frontal fibrosing alopecia and lichen planopilaris.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This case report illustrates that fibrosing alopecia in a pattern distribution may be misdiagnosed as androgenetic alopecia due to similar hair loss patterns, but distinctive trichoscopic and histopathologic features help differentiate it.

In this case report, topical application of fluocinolone acetonide acetate ointment increased hair length and thickness in three family members with congenital hypotrichosis.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

Avoiding certain allergens in personal care products may improve symptoms for some patients with lichen planopilaris or frontal fibrosing alopecia.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

This study examined the role of long non-coding RNAs in wool fineness among Gansu alpine fine-wool sheep, identifying specific lncRNAs and target genes that may enhance wool quality.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

In this study, the researchers developed a computer-aided imaging system to quantitatively measure baldness in Chinese women with female pattern hair loss, potentially improving the precision of severity evaluation compared to traditional scales.

In this case study, a 24-year-old woman with frontal alopecia resembling frontal fibrosing alopecia was ultimately diagnosed with primary cutaneous follicle center lymphoma, highlighting the critical role of biopsy in identifying atypical alopecia presentations.

This study reported no significant improvement in patients with frontal fibrosing alopecia treated with various therapeutic agents, highlighting the need for more evidence-based treatments, especially in those with active disease.

This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.

This study found that Finasteride significantly reduced the proliferation of acute myeloid leukemia cell lines by inhibiting androgen receptor activity.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

This study found that the SBN system effectively evaluates and describes the severity and clinical variant of alopecia areata using a standardized scale, aiding in patient management and disease course prediction.

This study concluded that Flutamide-loaded solid lipid nanoparticles may enhance hair follicle drug delivery and promote hair growth in androgenic alopecia compared to a Flutamide hydroalcoholic solution.

Contact allergies might contribute to frontal fibrosing alopecia.

This study found that higher-dose fluconazole (400 mg/d) for two months or longer commonly causes reversible alopecia, which can be resolved by discontinuing or reducing the dosage.

This study found that loss of the folliculin protein delays transferrin receptor recycling, leading to iron deficiency and suggesting a role in the mechanisms of Birt-Hogg-Dubé syndrome.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This study observed that progressive frontal recession in postmenopausal women may exhibit features of fibrosing alopecia, suggesting a distinct reaction pattern from typical lichen planopilaris.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.